BioSpace News Archive

Suvoda LLC announced that its Director of Services Delivery, Europe will be a key presenter and panelist in two sessions at the upcoming Clinical Trial Supply Europe conference in Madrid, Spain taking place from March 22–23.

THINK Surgical, Inc., an innovator in the field of orthopedic robotic surgery, proudly announced Centennial Hills Hospital Medical Center became the first facility in the western United States to utilize the latest iteration of the TSolution One robot from THINK Surgical.

Advaxis, Inc. today announces its financial results for the first quarter ended January 31, 2022 and provides a business update.

Seton Pharmaceuticals, LLC and Senores Pharmaceuticals, Inc. today announced the launch of Butalbital, Acetaminophen and Caffeine Capsules USP, 50 mg/325 mg/40 mg, a therapeutic equivalent of the reference listed drug Butalbital, Acetaminophen, and Caffeine capsules of Mayne Pharma, Inc. in the U.S. market.

Volta Labs, a bioautomation company developing solutions to streamline the upstream workflows in genomic sequencing, announced it raised $20 million in a Series A funding.

Capsulomics, an early detection cancer diagnostic company, announced the appointment of Bill Stevens as Chief Financial Officer.

Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, is pleased to announce today that it has made several strategic additions to its Scientific Advisory Board (“SAB”).

Shanghai Stock Exchange listed company (688222.SH) HitGen Inc. (“HitGen”) today announced that it has entered into a research collaboration agreement with Howard Hughes Medical Institute (“HHMI”) and Duke University.

Purdue Pharma L.P. is accepting proposals for investigator-initiated research (IIR) to assess opioid overdose reversal in Emergency Department (ED) and Emergency Medical Service (EMS) settings.

Moderna, Inc. announced that Health Canada has approved the use of Moderna’s mRNA COVID-19 vaccine, SPIKEVAX™, in a two-dose series of 50 µg per dose for active immunization to prevent COVID-19 caused by SARS-CoV-2 in children aged 6 to11 years.